Robert Mashal Biography and Net Worth

Director of Nuvation Bio

Robert currently serves as a consultant to the life sciences industry. Previously, he was the Global Head of Strategy for the Immunology and Oncology franchises at Sanofi. Robert has worked as CEO of NKT Therapeutics and Alinea Pharmaceuticals, two venture capital backed life sciences firms. He was a partner at Boston Millennia Partners, a private equity firm, where he was on the Board of Directors of Glycofi, Cardiomems, and Sapphire Therapeutics. He served as a Program Executive at Vertex Pharmaceuticals, where he was on the Joint Steering Committee for the Vertex-Novartis kinase collaboration. He was also a consultant at McKinsey and Company. Prior to McKinsey, Dr. Mashal was a board-certified medical oncologist and received his training in internal medicine at the University of California, San Francisco, and in oncology at the Dana-Farber Cancer Institute. Dr. Mashal received his B.A. and M.D. degrees from Johns Hopkins University.

What is Robert Mashal's net worth?: The estimated net worth of Robert Mashal is at least $247,500.00 as of October 8th, 2024. Dr. Mashal owns 100,000 shares of Nuvation Bio stock worth more than $247,500 as of May 2nd. This net worth approximation does not reflect any other investments that Dr. Mashal may own. Learn More about Robert Mashal's net worth.
How do I contact Robert Mashal?: The corporate mailing address for Dr. Mashal and other Nuvation Bio executives is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. Nuvation Bio can also be reached via phone at 332-208-6102 and via email at ir@nuvationbio.com. Learn More on Robert Mashal's contact information.
Has Robert Mashal been buying or selling shares of Nuvation Bio?: Robert Mashal has not been actively trading shares of Nuvation Bio over the course of the past ninety days. Most recently, on Tuesday, October 8th, Robert Mashal bought 100,000 shares of Nuvation Bio stock. The stock was acquired at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company's stock, valued at $220,000. Learn More on Robert Mashal's trading history.
Who are Nuvation Bio's active insiders?: Nuvation Bio's insider roster includes Kim Blickenstaff (Director), Xiangmin Cui (Director), Jennifer Fox (CFO & Sec. ), David Hung (Founder), David Hung (CEO), Robert Mashal (Director), and Oleg Nodelman (Director). Learn More on Nuvation Bio's active insiders.
Are insiders buying or selling shares of Nuvation Bio?: During the last year, Nuvation Bio insiders bought shares 6 times. They purchased a total of 1,196,778 shares worth more than $2,803,500.47. The most recent insider tranaction occured on April, 7th when CEO David Hung bought 300,000 shares worth more than $486,000.00. Insiders at Nuvation Bio own 29.9% of the company. Learn More about insider trades at Nuvation Bio.
Information on this page was last updated on 4/7/2025.

Robert Mashal Insider Trading History at Nuvation Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/8/2024	Buy	100,000	$2.20	$220,000.00	100,000

Robert Mashal Buying and Selling Activity at Nuvation Bio

Nuvation Bio Company Overview

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Today's Range

Now: $2.48

$2.31

$2.54

50 Day Range

MA: $1.95

$1.65

$2.31

2 Week Range

Now: $2.48

$1.54

$3.97

Volume

3,675,625 shs

Average Volume

2,127,058 shs

Market Capitalization

$838.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47